Catherine Hottin

Mrs. Catherine Hottin

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2022 in Cells
Verified
Journal Article
Open access
PDF file
CHCatherine Hottin
Catherine Hottin
MPMuriel Perron
Muriel Perron
JRJérôme E Roger
Jérôme E Roger
Glycogen synthase kinase 3 (GSK3) is a key regulator of many cellular signaling processes and performs a wide range of biological functions in the nervous system. Due to its central role in numerous cellular processes involved in cell degeneration, a rising number of studies have highlighted the interest in developing therapeutics targeting GSK3 to treat neurodegenerative diseases. Although recent works strongly suggest that inhibiting GSK3 might also be a promising therapeutic approach for retinal degenerative diseases, its full potential is still under-evaluated. In this review, we summarize the literature on the role of GSK3 on the main cellular functions reported as deregulated during retinal degeneration, such as glucose homeostasis which is critical for photoreceptor survival, or oxidative stress, a major component of retinal degeneration. We also discuss the interest in targeting GSK3 for its beneficial effects on inflammation, for reducing neovascularization that occurs in some retinal dystrophies, or for cell-based therapy by enhancing Müller glia cell proliferation in diseased retina. Together, although GSK3 inhibitors hold promise as therapeutic agents, we highlight the complexity of targeting such a multitasked kinase and the need to increase our knowledge of the impact of reducing GSK3 activity on these multiple cellular pathways and biological processes.

30 July 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YZYu Zhu
Yu Zhu
LPLucia Peiroten
Lucia Peiroten
PKPranav Nanda Kumar
Pranav Nanda Kumar
CHCatherine Hottin
Catherine Hottin
KJKangwei Jiao
Kangwei Jiao
FPFrançois Paquet-Durand
François Paquet-Durand
Retinitis Pigmentosa (RP) is the most common inherited retinal degeneration, characterized by an initial loss of rod photoreceptor cells. Photoreceptor cell death has been associated with high levels of cyclic guanosine-3′, 5′- monophosphate (cGMP) in animal models of autosomal recessive RP (ARRP) and autosomal dominant RP (ADRP). cGMP analogues inhibiting protein kinase G (PKG) have been found to prevent rod degeneration in ARRP disease models, but their effects on ADRP are unknown. Here, we used the recently generated rhodopsin-mutant Rho I255d/+ ADRP mouse model to study cGMP-signaling and the effects of cGMP analogues targeting PKG. cGMP accumulation was investigated by retinal immunostaining in wild-type (WT), Rho I255d/+, and Rho I255d/I255d mice. The therapeutic efficacy of the cGMP analogues CN03 and CN238 was evaluated on organotypic retinal explant cultures derived from WT and Rho I255d/+ mice. Readouts included the TUNEL assay and immunostaining for cone arrestin-3. Downstream effectors of cell death were visualized using calpain, poly-ADP-ribose polymerase (PARP), and histone deacetylase (HDAC) in situ assays, as well as caspase-3 immunostaining. Photoreceptor function was assessed using micro-electroretinogram (µERG) recordings. When compared with WT, Rho I255d photoreceptors displayed cGMP accumulation in outer segments. In the Rho I255d/+ ADRP model, CN03 and CN238 significantly reduced the number of dying photoreceptors. However, the relatively small number of photoreceptors exhibiting caspase-3 activity was not changed by the treatment. Remarkably, CN238 effectively provided long-lasting neuroprotection of cone photoreceptors and preserved retinal light responsiveness of Rho I255d/+ retina. Overall, this study suggests caspase-independent but cGMP-dependent cell death as a dominant degenerative mechanism in the Rho I255d/+ ADRP mouse model. PKG inhibition demonstrated robust neuroprotection of both rod and cone photoreceptors, while the marked preservation of retinal function, especially with the compound CN238, highlighted cGMP analogues for the treatment of ADRP.

21 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
YZYu Zhu
Yu Zhu
LPLucia Peiroten
Lucia Peiroten
PKPranav Nanda Kumar
Pranav Nanda Kumar
CHCatherine Hottin
Catherine Hottin
WHWadood Haq
Wadood Haq
FPFrançois Paquet-Durand
François Paquet-Durand
Retinitis Pigmentosa (RP) is the most common inherited retinal degeneration, characterized by an initial loss of rod photoreceptor cells. Photoreceptor cell death has been associated with high levels of cyclic guanosine-3′, 5′-monophosphate (cGMP) in animal models of autosomal recessive RP (ARRP) and autosomal dominant RP (ADRP). cGMP analogues inhibiting protein kinase G (PKG) have been found to prevent rod degeneration in ARRP disease models, but their effects on ADRP are unknown. Here, we used the recently generated rhodopsin-mutant Rho I255d/+ ADRP mouse model to investigate cGMP-signaling and the effects of cGMP analogues targeting PKG. cGMP accumulation was investigated by retinal immunostaining in wild-type (WT), Rho I255d/+ , and Rho I255d/I255d mice. The therapeutic efficacy of the cGMP analogues CN03 and CN238 was evaluated on organotypic retinal explant cultures derived from WT and Rho I255d/+ mice. Readouts included the TUNEL assay and immunostaining for cone arrestin-3. Downstream effectors of cell death were visualized using calpain, poly-ADP-ribose polymerase (PARP), and histone deacetylase (HDAC) in situ assays, as well as caspase-3 immunostaining. Photoreceptor function was assessed using micro-electroretinogram (µERG) recordings. When compared with WT, Rho I255d photoreceptors displayed cGMP accumulation in outer segments. In the Rho I255d/+ ADRP model, CN03 and CN238 significantly reduced the number of dying photoreceptors. However, the relatively small number of photoreceptors exhibiting caspase-3 activity was not changed by the treatment. Remarkably, CN238 effectively provided long-lasting neuroprotection of cone photoreceptors and preserved retinal light responsiveness of Rho I255d/+ retina. Overall, this study suggests caspase-independent but cGMP-dependent cell death as a dominant degenerative mechanism in the Rho I255d/+ ADRP mouse model. PKG inhibition demonstrated robust neuroprotection of both rod and cone photoreceptors, while the marked preservation of retinal function, especially with the compound CN238, highlighted cGMP analogues for the treatment of ADRP.

8 April 2026
Verified
Thesis
Closed access
CHCatherine Hottin
Catherine Hottin
Deciphering the Neuroprotective Effects of GSK3 Signaling in the Retina: Les maladies dégénératives de la rétine représentent un défi majeur en ophtalmologie du fait de leur hétérogénéité clinique et génétique. Le développement de thérapies efficaces pour empêcher la perte de cellules rétiniennes dans ces maladies nécessite une compréhension approfondie des mécanismes moléculaires sous-jacents. Dans cette étude, nous avons exploré le potentiel de l'inhibition de la Glycogène Synthase Kinase 3 (GSK3) en tant que stratégie neuroprotectrice pour les maladies dégénératives de la rétine. Notre objectif était d'identifier de nouveaux candidats thérapeutiques, cibles de GSK3, pour préserver les photorécepteurs.En utilisant un modèle murin, nous avons conditionnellement délété Gsk3α ou Gsk3β grâce à l'expression de la Pax6α-Cre recombinase spécifiquement dans toutes les cellules de la rétine. Afin de tester l'effet sur la survie des photorécepteurs, deux modèles de dégénérescence ont été utilisés : ex vivo dans des cultures d'explants rétiniens et in vivo sous l'action du N-méthyl-N-nitrosourée (MNU). Nous avons démontré qu'une inhibition génétique de GSK3 avait un effet neuroprotecteur sur les photorécepteurs en condition de dégénérescence. Une analyse transcriptomique (RNA-seq) sur des rétines portant un seul allèle de Gsk3α en conditions de dégénérescence ont conduit à l'identification de 350 gènes différentiellement exprimés.De manière intéressante, plusieurs facteurs ayant des propriétés neuroprotectrices, tels que le Fgf2, Gdnf, Pgf, Spp1 et Vgf, ont été identifiés et représentent donc des candidats potentiels pour expliquer les effets neuroprotecteurs de la perte partielle de GSK3.Des analyses complémentaires de protéomiques (LC-MS/MS) ont permis de mettre en évidence 121 protéines dérégulées en conditions dégénératives. Nous avons identifié une nouvelle cible directe potentielle de GSK3, l'Extracellular Signal-Regulated Kinase 3 (ERK3). Cette kinase est surexprimée dans notre modèle d'inhibition génétique de GSK3, et possède des sites putatifs de phosphorylation par GSK3. D'autre part, les souris ERK3 kinase-dead, exprimant une ERK3 non fonctionnelle, présentent une mort accrue des photorécepteurs suite à l'injection de MNU, suggérant l'implication d'ERK3 dans la neuroprotection.En conclusion, notre étude non seulement a mis en lumière les effets neuroprotecteurs de l'inhibition de GSK3 mais a permis également d'identifier de nouveaux facteurs régulés par la signalisation GSK3, et impliquées dans la neuroprotection. Ces facteurs représentent donc de nouvelles cibles thérapeutiques potentielles pour préserver la vision chez les patients atteints de dégénérescence rétinienne.